For example, inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) that are used to treat metastatic ER+ breast cancer can induce the production of T cell–attracting chemokines in tumors and promote T cell responses (19, 20). This evidence concerns the gene CDK4 and breast carcinoma.